Procter & Gamble Earnings Beat on Sales Growth
Procter & Gamble earnings beat as Q3 net sales were $21.2B with 3% organic growth, though a Glad joint venture gain clouds near-term durability.
KEY TAKEAWAYS
- Net sales rose 7% to $21.2 billion while organic sales increased 3%.
- Diluted net EPS was $1.63, up 6%, aided by a one-time Glad joint venture gain.
- Company reiterated its full-year fiscal 2026 forecast, leaving durability of profit growth in focus.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Procter & Gamble earnings beat estimates on April 24, 2026, as the company reported stronger quarterly sales and said a gain from dissolving its Glad joint venture helped results while it reiterated its full-year fiscal 2026 forecast.
Sales and Earnings Beat
Procter & Gamble said net sales in its fiscal third quarter, the three months ended March 31, 2026, rose 7.0% year-over-year to $21.2 billion. Organic sales growth, which excludes foreign-exchange effects and acquisitions or divestitures, increased 3.0%.
Diluted net earnings per share rose 6.0% to $1.63, while net income increased to $3.9 billion from $3.8 billion a year earlier. The company attributed part of the earnings gain to a one-time profit from dissolving the Glad joint venture.
Guidance and Market Context
The company reiterated its full-year fiscal 2026 forecast after releasing the quarter’s results. Its reported revenue and earnings exceeded pre-quarter consensus estimates of about $20.6 billion and $1.56 per share, respectively.
The combination of a one-time gain and the 3.0% organic sales growth leaves investors assessing how much of the profit increase reflects sustained demand versus nonrecurring items. Market participants will watch upcoming quarters for signs that organic growth continues or accelerates beyond this period.
